Daily CSR
Daily CSR

Daily CSR

Daily news about corporate social responsibility, ethics and sustainability
Tags (3) : biologics

Arcera–Fosun Pharma MoU to Boost Global Life Sciences & Neuroscience Innovation

Arcera–Fosun Pharma MoU to Boost Global Life Sciences & Neuroscience Innovation
04/28/2026 | Companies
Arcera Life Sciences a global life sciences firm based in Abu Dhabi, and Shanghai Fosun Pharmaceutical Group Co Ltd, an innovation-led international pharmaceutical and healthcare company, have announced the signing of a Memorandum of Understanding (MoU). This agreement establishes a long-term...
Abu Dhabi, Alzheimer’s disease, Arcera Life Sciences, biologics, biotechnology, biotechnology incubation, cardiometabolic diseases, cell therapy, China, drug development, emerging markets, Fosun Pharma, gene therapy, global healthcare, healthcare infrastructure, innovation, international collaboration, joint ventures, licensing, life sciences, market access, memorandum of understanding, Middle East healthcare, MoU, neurodegenerative diseases, neuroscience, oncology, pharmaceutical industry, R&D, radiopharmaceuticals, rare diseases, research and development, siRNA therapies, small molecules, strategic partnership, UAE, Vision 2030

Harbour BioMed Reports Positive Phase I Results for HBM9378 Antibody Therapy

Harbour BioMed Reports Positive Phase I Results for HBM9378 Antibody Therapy
03/23/2026 | Companies
Harbour BioMed, a global biopharmaceutical company focused on advancing innovative antibody-based therapies in immunology and immune-oncology, has announced the online publication of results from the first-in-human Phase I clinical trial (NCT05790694/CTR20221961) of HBM9378 (also referred to as...
antibody therapeutics, biologics, biotech innovation, chronic obstructive pulmonary disease, clinical research, COPD, drug development, half-life extension, Harbour BioMed, HBM9378, immune-oncology, immunological disorders, immunology, Kelun-Biotech, monoclonal antibody, pharmacokinetics, Phase I clinical trial, respiratory medicine, safety profile, severe asthma, SKB378, TSLP inhibitor, WIN378

Teva’s Global Innovation Strategy: Advancing Healthcare Through Collaboration and Research

Teva’s Global Innovation Strategy: Advancing Healthcare Through Collaboration and Research
06/18/2025 | Companies
Advancing Access to Healthcare through Innovation and Partnerships Expanding access to medicines and healthcare relies on the continuous creation of evidence-driven solutions to address unmet medical needs. To support this mission, we actively engage in collaborative scientific efforts with...
academic partnerships, academic research, AI drug development, AI in healthcare, AION Labs, BioInnovators Forum, biologics, biomarkers, clinical trials, disease burden, drug discovery, epidemiology, healthcare access, healthcare innovation, IMI, innovation, Israeli biotech, medical education, neurodegenerative diseases, Organospheres, patient access, pharmaceutical research, pharmaceutical startups, public health research, public-private partnerships, PubMed publications, R&D, scientific collaboration, Teva Pharmaceuticals, translational medicine, unmet medical needs


Want to write a piece for Daily CSR? Please contact us by email at editor[@]dailycsr.com